There are 2934 resources available
MMR repair driven neoantigens
Presenter: Alberto Bardelli
Session: Tumour neoantigens
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Alberto Bardelli
Session: Tumour neoantigens
Resources:
Slides
Webcast
Proffered Paper - Breast cancer, early stage - Invited Discussant LBA18 and LBA19
Presenter: Antonio Llombart Cussac
Session: Proffered Paper - Breast cancer, early stage
Resources:
Slides
Webcast
Proffered Paper - Breast cancer, early stage - Invited Discussant 174O and 175O
Presenter: Christos Sotiriou
Session: Proffered Paper - Breast cancer, early stage
Resources:
Slides
Webcast
6254 - Results of the TAPPAS trial: An adaptive enrichment Phase 3 trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)
Presenter: Robin Lewis Jones
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
3086 - CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumor (DT) patients (pts)
Presenter: Jean-Emmanuel Kurtz
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
5459 - IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- Soft-tissue sarcoma cohort
Presenter: Javier Martin Broto
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
2274 - ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
Presenter: Takayuki Yoshino
Session: Adjuvant treatment duration for high-risk stage II colon cancer
Resources:
Abstract
Slides
Webcast
6136 - Clinical Outcomes by Chemotherapy Regimen in Patients with RS 26-100 in TAILORx
Presenter: Joseph Sparano
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
4667 - Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
Presenter: Michael Untch
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast